// App-Quantinova.ai

: High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study

Researchers

Presenter

  • Franco Locatelli

Principal Investigators

  • Gerhard Zugmaier

  • Peter Bader

  • Sima Jeha

  • Paul-Gerhardt Schlegel

  • Jean-Pierre Bourquin

  • Rupert Handgretinger

  • Benoit Brethon

  • Claudia Rossig

  • Christiane Chen-Santel

Medical Centers

  • Department of Pediatric Hematology and Oncology, Cell and Gene Therapy,IRCCS Bambino Gesù Children's Hospital,Roma,Italy

  • Amgen Research GmbH, Munich, Germany

  • Department for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • University Childrens Hospital Freiburg, Freiburg, Germany

  • Department of Oncology and Childrens Research Center, University Childrens Hospital, Zurich, Switzerland

  • Pediatric Hematology and Oncology, University Children Hospital Tuebingen Germany, Tuebingen, Germany

  • Pediatric Hematology and Immunology Department, Robert Debre hospital, APHP, Paris, France

  • University Childrens Hospital Munster, Muenster, Germany.

  • Charite-University Medicine Berlin, Berlin, Germany

Locations

  • Italy

  • Germany

  • United States

  • Switzerland

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT02187354

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved